18
Participants
Start Date
May 31, 2015
Primary Completion Date
August 16, 2019
Study Completion Date
August 16, 2019
Dendritic cell based cryoimmunotherapy
Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
Cyclophosphamide
Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
ipilimumab
The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
Haukeland University Hospital Research Department, Bergen
Haukeland University Hospital
OTHER
Norwegian Radium Hospital
OTHER
Alden Cancer Therapy II
INDUSTRY